WRAP53

WD repeat containing antisense to TP53, the group of WD repeat domain containing

Basic information

Region (hg38): 17:7686071-7703502

Previous symbols: [ "WDR79" ]

Links

ENSG00000141499NCBI:55135OMIM:612661HGNC:25522Uniprot:Q9BUR4AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • dyskeratosis congenita, autosomal recessive 3 (Definitive), mode of inheritance: AR
  • dyskeratosis congenita (Supportive), mode of inheritance: AD
  • dyskeratosis congenita, autosomal recessive 3 (Moderate), mode of inheritance: AR
  • dyskeratosis congenita, autosomal recessive 3 (Strong), mode of inheritance: AR
  • dyskeratosis congenita (Moderate), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Dyskeratosis congenita, autosomal recessive 3ARHematologic; Oncologic; PulmonarySurveillance (eg, with regularly performed CBC as well as other measures in the presence of concern for hematologic sequelae) for bone marrow failure, as well as surveillance for multiple cancer types (eg, with self-examination and clinical examination), and pulmonary disease may allow early detection and treatment; Lung transplant may be indicated in individuals with advanced lung diease; HSCT may be indicated due to manifestations including leukemia and bone marrow failure (which may also be treated with androgen therapy), but the long-term efficacy may not be optimalDermatologic; Hematologic; Oncologic; Pulmonary21205863; 20301779

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the WRAP53 gene.

  • Hereditary cancer-predisposing syndrome (1 variants)
  • Dyskeratosis congenita, autosomal recessive 3 (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the WRAP53 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
2
clinvar
103
clinvar
1
clinvar
106
missense
1
clinvar
2
clinvar
197
clinvar
5
clinvar
3
clinvar
208
nonsense
2
clinvar
2
start loss
1
clinvar
1
frameshift
1
clinvar
1
clinvar
20
clinvar
22
inframe indel
2
clinvar
2
splice donor/acceptor (+/-2bp)
0
splice region
10
21
31
non coding
22
clinvar
57
clinvar
14
clinvar
93
Total 2 3 246 165 18

Variants in WRAP53

This is a list of pathogenic ClinVar variants found in the WRAP53 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
17-7687108-C-T Hereditary cancer-predisposing syndrome Likely benign (Dec 01, 2015)224043
17-7687368-G-A not specified Likely benign (Oct 30, 2017)516754
17-7687372-C-A Squamous cell carcinoma of the head and neck Uncertain significance (May 28, 2019)803311
17-7687373-T-G Uncertain significance (Dec 27, 2013)127803
17-7687375-AC-A Hereditary cancer-predisposing syndrome Uncertain significance (Nov 10, 2021)1692472
17-7687376-C-A Li-Fraumeni syndrome Uncertain significance (Nov 09, 2023)2697350
17-7687376-C-G Li-Fraumeni syndrome • Hereditary cancer-predisposing syndrome Conflicting classifications of pathogenicity (Oct 05, 2023)1524222
17-7687376-C-T Li-Fraumeni syndrome Uncertain significance (Jan 18, 2024)1415968
17-7687390-G-A Uncertain significance (Apr 26, 2017)246194
17-7687391-C-A Squamous cell carcinoma of the head and neck Likely benign (May 28, 2019)803312
17-7687396-C-T not specified Uncertain significance (Jan 12, 2018)265275
17-7687421-G-T Li-Fraumeni syndrome • Dyskeratosis Congenita, Recessive Uncertain significance (Jun 14, 2016)325644
17-7687442-G-A Dyskeratosis Congenita, Recessive • Li-Fraumeni syndrome 1 Uncertain significance (Apr 27, 2017)325645
17-7687450-G-C Dyskeratosis Congenita, Recessive • Li-Fraumeni syndrome 1 Uncertain significance (Jan 12, 2018)325646
17-7687459-T-C not specified Uncertain significance (Nov 14, 2016)437015
17-7687471-G-A Li-Fraumeni syndrome 1 Uncertain significance (Mar 30, 2018)891589
17-7688193-C-CG Benign (May 25, 2021)1182360
17-7688222-T-C Likely benign (Feb 04, 2019)1193678
17-7688236-G-A Benign (Jul 05, 2018)1274330
17-7688237-T-A Benign (Jul 05, 2018)1271401
17-7688335-T-G Dyskeratosis Congenita, Recessive Uncertain significance (Jun 14, 2016)369234
17-7688394-G-A Dyskeratosis congenita, autosomal recessive 3 Uncertain significance (Jan 13, 2018)325647
17-7688404-G-C Li-Fraumeni syndrome • Dyskeratosis congenita, autosomal recessive 3 Benign/Likely benign (Jan 13, 2018)369235
17-7688443-G-A Li-Fraumeni syndrome • Dyskeratosis congenita, autosomal recessive 3 Benign/Likely benign (Jan 12, 2018)369236
17-7688501-C-T Dyskeratosis congenita, autosomal recessive 3 Uncertain significance (Jan 13, 2018)891590

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
WRAP53protein_codingprotein_codingENST00000316024 1017432
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.00005350.9991257060421257480.000167
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.02023153160.9970.00001993543
Missense in Polyphen109121.680.895821291
Synonymous-0.08171291281.010.000008231129
Loss of Function2.821228.20.4260.00000179271

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0003220.000322
Ashkenazi Jewish0.000.00
East Asian0.00005440.0000544
Finnish0.00009290.0000924
European (Non-Finnish)0.0002380.000237
Middle Eastern0.00005440.0000544
South Asian0.00003270.0000327
Other0.0001630.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: RNA chaperone that plays a key role in telomere maintenance and RNA localization to Cajal bodies (PubMed:29804836, PubMed:29695869). Specifically recognizes and binds the Cajal body box (CAB box) present in both small Cajal body RNAs (scaRNAs) and telomerase RNA template component (TERC) (PubMed:19285445, PubMed:20351177, PubMed:29804836, PubMed:29695869). Essential component of the telomerase holoenzyme complex, a ribonucleoprotein complex essential for the replication of chromosome termini that elongates telomeres in most eukaryotes (PubMed:19179534, PubMed:20351177, PubMed:26170453, PubMed:29695869). In the telomerase holoenzyme complex, required to stimulate the catalytic activity of the complex (PubMed:27525486, PubMed:29804836). Acts by specifically binding the CAB box of the TERC RNA and controlling the folding of the CR4/CR5 region of the TERC RNA, a critical step for telomerase activity (PubMed:29804836). In addition, also controls telomerase holoenzyme complex localization to Cajal body (PubMed:22547674). During S phase, required for delivery of TERC to telomeres during S phase and for telomerase activity (PubMed:29804836). In addition to its role in telomere maintenance, also required for Cajal body formation, probably by mediating localization of scaRNAs to Cajal bodies (PubMed:19285445, PubMed:21072240). Also plays a role in DNA repair: phosphorylated by ATM in response to DNA damage and relocalizes to sites of DNA double-strand breaks to promote the repair of DNA double-strand breaks (PubMed:25512560, PubMed:27715493). Acts by recruiting the ubiquitin ligase RNF8 to DNA breaks and promote both homologous recombination (HR) and non- homologous end joining (NHEJ) (PubMed:25512560, PubMed:27715493). {ECO:0000269|PubMed:19179534, ECO:0000269|PubMed:19285445, ECO:0000269|PubMed:20351177, ECO:0000269|PubMed:21072240, ECO:0000269|PubMed:22547674, ECO:0000269|PubMed:25512560, ECO:0000269|PubMed:26170453, ECO:0000269|PubMed:27525486, ECO:0000269|PubMed:27715493, ECO:0000269|PubMed:29695869, ECO:0000269|PubMed:29804836}.;
Disease
DISEASE: Dyskeratosis congenita, autosomal recessive, 3 (DKCB3) [MIM:613988]: A rare multisystem disorder caused by defective telomere maintenance. It is characterized by progressive bone marrow failure, and the clinical triad of reticulated skin hyperpigmentation, nail dystrophy, and mucosal leukoplakia. Common but variable features include premature graying, aplastic anemia, low platelets, osteoporosis, pulmonary fibrosis, and liver fibrosis among others. Early mortality is often associated with bone marrow failure, infections, fatal pulmonary complications, or malignancy. {ECO:0000269|PubMed:21205863, ECO:0000269|PubMed:21602826}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Metabolism of proteins;Chaperonin-mediated protein folding;Association of TriC/CCT with target proteins during biosynthesis;Telomere Extension By Telomerase;Extension of Telomeres;Telomere Maintenance;Chromosome Maintenance;Protein folding;Cell Cycle (Consensus)

Recessive Scores

pRec
0.103

Intolerance Scores

loftool
0.759
rvis_EVS
-0.57
rvis_percentile_EVS
18.9

Haploinsufficiency Scores

pHI
0.145
hipred
N
hipred_score
0.435
ghis
0.562

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
E
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.649

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Wrap53
Phenotype
immune system phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);

Gene ontology

Biological process
DNA repair;telomere maintenance via telomerase;Cajal body organization;telomere formation via telomerase;RNA folding;positive regulation of DNA repair;positive regulation of telomerase activity;scaRNA localization to Cajal body;telomerase RNA localization to Cajal body;positive regulation of establishment of protein localization to telomere;protein localization to Cajal body;positive regulation of double-strand break repair via homologous recombination;positive regulation of double-strand break repair;positive regulation of double-strand break repair via nonhomologous end joining
Cellular component
chromosome, telomeric region;nucleoplasm;telomerase holoenzyme complex;cytosol;Cajal body;nuclear body;site of double-strand break
Molecular function
RNA binding;protein binding;ubiquitin protein ligase binding;histone binding;identical protein binding;protein-containing complex binding;chaperone binding;telomerase RNA binding